AzTrials
AzTrials

Bronchiectasis With Pseudomonas Aeruginosa ColonizationPhase 2CLEARNCT07088926

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

A Phase 2 study testing AZD0292 in people with Bronchiectasis With Pseudomonas Aeruginosa Colonization, run by AstraZeneca at 186 sites in 25 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA. Read more about this study

Who is it for?
Ages 12 years and older
What is being tested?
AZD0292
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
435 participants
Where
186 sitesin 25 countries
Study dates
6 Nov 2025to 14 Jun 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Participant must be ≥ 12 years of age at the time of signing the informed consent/assent
  • Weight ≥ 35 kg
  • Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility.
  • Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics
  • Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization
  • Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening.
Show all 9Show fewer
  • Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening
  • Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study. Participants who experience an exacerbation during the screening period and receive antibiotic therapy remain eligible for the study if the presence of culture-positive PsA is confirmed prior to randomization.
  • Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol

Who cannot join

  • Primary lung diagnosis other than bronchiectasis
  • Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Participants currently receiving treatment for active tuberculosis or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy
  • Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment
  • Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed
  • Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment
  • AIDS or Advanced human immunodeficiency virus disease (CD4 count of < 200 cells/mm3)
Show all 12Show fewer
  • History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration
  • Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening
  • Chronic immunosuppressive therapy (including prednisolone > 5 mg or equivalent) newly initiated within the last 3 months
  • Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study
  • Participants with CF on CFTR modulator therapies which are newly initiated within the previous 3 months prior to screening
  • Female participants who are pregnant, lactating, or WOCBP and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration

Trial locations and contacts

186 sites in 25 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

186 sites in 25 countries

United States25 sites, 18 recruiting

  • Research Site

    Ann Arbor, Michigan, 48109

    Recruiting

  • Research Site

    Austin, Texas, 78705

    Withdrawn

  • Research Site

    Charleston, South Carolina, 29425

    Recruiting

  • Research Site

    Denver, Colorado, 80206

    Not yet recruiting

  • Research Site

    Detroit, Michigan, 48202

    Withdrawn

  • Research Site

    DuBois, Pennsylvania, 15801

    Withdrawn

  • Research Site

    Jacksonville, Florida, 32209

    Recruiting

  • Research Site

    Kansas City, Kansas, 66160

    Recruiting

  • Research Site

    Mansfield, Texas, 76063

    Recruiting

  • Research Site

    Miami Lakes, Florida, 33014

    Terminated

  • Research Site

    Naples, Florida, 34102

    Recruiting

  • Research Site

    New Bern, North Carolina, 28562

    Recruiting

  • Research Site

    New York, New York, 10016

    Recruiting

  • Research Site

    Orange, California, 92868

    Recruiting

  • Research Site

    Ormond Beach, Florida, 32174

    Recruiting

  • Research Site

    Philadelphia, Pennsylvania, 19104

    Recruiting

  • Research Site

    Plantation, Florida, 33324

    Recruiting

  • Research Site

    Rincon, Georgia, 31326

    Recruiting

  • Research Site

    Rochester, Minnesota, 55905

    Withdrawn

  • Research Site

    Rock Hill, South Carolina, 29732

    Withdrawn

  • Research Site

    San Francisco, California, 94143

    Recruiting

  • Research Site

    St Louis, Missouri, 63130

    Recruiting

  • Research Site

    Tulsa, Oklahoma, 74133

    Withdrawn

  • Research Site

    Washington D.C., District of Columbia, 20007

    Recruiting

  • Research Site

    Winston-Salem, North Carolina, 27104

    Not yet recruiting

Other trials in United States

Japan14 sites, 14 recruiting

  • Research Site

    Bunkyō City, 113-8655

    Not yet recruiting

  • Research Site

    Gifu, 500-8717

    Recruiting

  • Research Site

    Hiratsuka-shi, 254-8502

    Recruiting

  • Research Site

    Kamogawa-shi, 296-0041

    Recruiting

  • Research Site

    Kiyose-shi, 204-8522

    Recruiting

  • Research Site

    Kiyose-shi, 204-8585

    Recruiting

  • Research Site

    Kurashiki-shi, 710-8602

    Recruiting

  • Research Site

    Meguro-ku, 153-0061

    Not yet recruiting

  • Research Site

    Miyazaki, 889-1692

    Recruiting

  • Research Site

    Nagasaki, 852-8501

    Recruiting

  • Research Site

    Ogi, 845-0032

    Recruiting

  • Research Site

    Shinjuku-ku, 160-8582

    Recruiting

  • Research Site

    Shinjuku-ku, 162-8655

    Recruiting

  • Research Site

    Urayasu-shi, 279-0021

    Recruiting

Other trials in Japan

Brazil11 sites, 9 recruiting

  • Research Site

    Blumenau, 89030-101

    Recruiting

  • Research Site

    Campinas, 13060-080

    Recruiting

  • Research Site

    Curitiba, 80030-110

    Recruiting

  • Research Site

    Curitiba, 80230-130

    Recruiting

  • Research Site

    Porto Alegre, 9061-000

    Recruiting

  • Research Site

    Porto Alegre, 90630-165

    Recruiting

  • Research Site

    Porto Alegre, 91350-200

    Withdrawn

  • Research Site

    Salvador, 40050-410

    Withdrawn

  • Research Site

    São José dos Campos, 12230-001

    Recruiting

  • Research Site

    São Paulo, 05.403-010

    Recruiting

  • Research Site

    São Paulo, 05403-000

    Recruiting

Other trials in Brazil

Germany9 sites, 8 recruiting

  • Research Site

    Berlin, 10117

    Recruiting

  • Research Site

    Darmstadt, 64283

    Withdrawn

  • Research Site

    Essen, 45239

    Recruiting

  • Research Site

    Frankfurt, 60596

    Recruiting

  • Research Site

    Halle, 06108

    Recruiting

  • Research Site

    Hanover, 30625

    Recruiting

  • Research Site

    Konstanz, 78464

    Recruiting

  • Research Site

    München, 80336

    Recruiting

  • Research Site

    München-Pasing, 81241

    Recruiting

Other trials in Germany

Peru9 sites, 6 recruiting

  • Research Site

    Bellavista, CALLAO 2

    Withdrawn

  • Research Site

    Callao, Bellavista

    Not yet recruiting

  • Research Site

    Lima, 15023

    Recruiting

  • Research Site

    Lima, 15036

    Recruiting

  • Research Site

    Lima, 15038

    Recruiting

  • Research Site

    Lima, 15082

    Not yet recruiting

  • Research Site

    Lima, 15088

    Withdrawn

  • Research Site

    Lima, LIMA 1

    Recruiting

  • Research Site

    Lima, LIMA 29

    Withdrawn

Other trials in Peru

South Korea9 sites, 9 recruiting

  • Research Site

    Anyang-si, 14068

    Recruiting

  • Research Site

    Cheongju-si, 28644

    Recruiting

  • Research Site

    Daegu, 42415

    Recruiting

  • Research Site

    Seongnam-si, 13620

    Recruiting

  • Research Site

    Seoul, 04763

    Recruiting

  • Research Site

    Seoul, 05030

    Recruiting

  • Research Site

    Seoul, 05505

    Recruiting

  • Research Site

    Seoul, 07441

    Recruiting

  • Research Site

    Ulsan, 44033

    Recruiting

Other trials in South Korea

United Kingdom9 sites, 9 recruiting

  • Research Site

    Belfast, BT9 7AB

    Recruiting

  • Research Site

    Birmingham, B9 5SS

    Recruiting

  • Research Site

    Brighton, BN2 1ES

    Recruiting

  • Research Site

    Cambridge, CB2 0AY

    Recruiting

  • Research Site

    Dundee, DD1 9SY

    Recruiting

  • Research Site

    Edinburgh, EH16 4SA

    Recruiting

  • Research Site

    Exeter, EX2 5DW

    Recruiting

  • Research Site

    Liverpool, L14 3PE

    Recruiting

  • Research Site

    Manchester, M23 9LT

    Recruiting

Other trials in United Kingdom

France8 sites, 8 recruiting

  • Research Site

    Brest, 29200

    Recruiting

  • Research Site

    Créteil, 94010

    Recruiting

  • Research Site

    Marseille, 13915

    Recruiting

  • Research Site

    Montpellier, 34295

    Recruiting

  • Research Site

    Paris, 75014

    Recruiting

  • Research Site

    Pessac, 33604

    Recruiting

  • Research Site

    Strasbourg, 67091

    Recruiting

  • Research Site

    Toulouse, 31100

    Recruiting

Other trials in France

Greece8 sites, 8 recruiting

  • Research Site

    Athens, 11527

    Recruiting

  • Research Site

    Athens, 12462

    Recruiting

  • Research Site

    Athens, 15126

    Recruiting

  • Research Site

    Athens, 17562

    Recruiting

  • Research Site

    Ioannina, 45500

    Recruiting

  • Research Site

    Larissa, 41110

    Recruiting

  • Research Site

    Pátrai, 26500

    Recruiting

  • Research Site

    Thessaloniki, 57010

    Recruiting

Other trials in Greece

Spain8 sites, 8 recruiting

  • Research Site

    Barcelona, 08003

    Recruiting

  • Research Site

    Barcelona, 08036

    Recruiting

  • Research Site

    Benalmádena, 29631

    Recruiting

  • Research Site

    Madrid, 28040

    Recruiting

  • Research Site

    Madrid, 28046

    Recruiting

  • Research Site

    Mérida, 06800

    Recruiting

  • Research Site

    Patraix, 46017

    Recruiting

  • Research Site

    Valencia, 46009

    Recruiting

Other trials in Spain

Canada7 sites, 6 recruiting

  • Research Site

    Ajax, Ontario, L1S 2J5

    Recruiting

  • Research Site

    Calgary, Alberta, T2N4Z6

    Recruiting

  • Research Site

    Québec, Quebec, G1V 4G5

    Recruiting

  • Research Site

    Saint-Charles-Borromée, Quebec, J6E 2B4

    Recruiting

  • Research Site

    Stoney Creek, Ontario, L8G 2V6

    Recruiting

  • Research Site

    Trois-Rivières, Quebec, G8T 7A1

    Withdrawn

  • Research Site

    Vancouver, British Columbia, V5Z 1M9

    Recruiting

Other trials in Canada

Italy7 sites, 7 recruiting

  • Research Site

    Milan, 20122

    Recruiting

  • Research Site

    Palermo, 90127

    Recruiting

  • Research Site

    Pavia, 27100

    Recruiting

  • Research Site

    Perugia, 06129

    Recruiting

  • Research Site

    Roma, 00163

    Recruiting

  • Research Site

    Rozzano, 20089

    Recruiting

  • Research Site

    Torrette, 60126

    Recruiting

Other trials in Italy

Taiwan7 sites, 7 recruiting

  • Research Site

    Kaohsiung City, 80756

    Recruiting

  • Research Site

    Taichung, 40447

    Recruiting

  • Research Site

    Taichung, 40705

    Recruiting

  • Research Site

    Taipei, 0116

    Recruiting

  • Research Site

    Taipei, 10002

    Recruiting

  • Research Site

    Taipei, 110

    Recruiting

  • Research Site

    Taoyuan, 333

    Recruiting

Other trials in Taiwan

Turkey (Türkiye)7 sites, 7 recruiting

  • Research Site

    Adana, 1330

    Recruiting

  • Research Site

    Ankara, 6340

    Recruiting

  • Research Site

    Diyarbakır, 21280

    Recruiting

  • Research Site

    Istanbul, 34098

    Recruiting

  • Research Site

    Istanbul, 34890

    Recruiting

  • Research Site

    Mersin, 33343

    Recruiting

  • Research Site

    Zeytinburnu, 34020

    Recruiting

Other trials in Turkey (Türkiye)

Israel6 sites, 6 recruiting

  • Research Site

    Ashkelon, 7830604

    Recruiting

  • Research Site

    Haifa, 34362

    Recruiting

  • Research Site

    Jerusalem, 00000

    Recruiting

  • Research Site

    Jerusalem, 91031

    Recruiting

  • Research Site

    Ramat Gan, 52621

    Recruiting

  • Research Site

    Tel Aviv, 6423906

    Recruiting

Other trials in Israel

Vietnam6 sites, 6 recruiting

  • Research Site

    Can Tho, 900000

    Not yet recruiting

  • Research Site

    Hà Nội, 100000

    Recruiting

  • Research Site

    Haiphong, 180000

    Recruiting

  • Research Site

    Hanoi, 100000

    Recruiting

  • Research Site

    Ho Chi Minh City, 700000

    Recruiting

  • Research Site

    Huế, 530000

    Recruiting

Other trials in Vietnam

Chile5 sites, 5 recruiting

  • Research Site

    Concepción, 4070196

    Recruiting

  • Research Site

    Santiago, 8150000

    Recruiting

  • Research Site

    Santiago, 8380453

    Recruiting

  • Research Site

    Talca, 3481349

    Recruiting

  • Research Site

    Viña del Mar, 2540364

    Recruiting

Other trials in Chile

Denmark5 sites, 4 recruiting

  • Research Site

    Aalborg, 9000

    Recruiting

  • Research Site

    Aarhus N, 8200

    Withdrawn

  • Research Site

    Hvidovre, 2650

    Recruiting

  • Research Site

    Odense C, 5000

    Recruiting

  • Research Site

    Roskilde, 4000

    Recruiting

Other trials in Denmark

Thailand5 sites, 5 recruiting

  • Research Site

    Bangkok, 10400

    Recruiting

  • Research Site

    Muang, 40002

    Recruiting

  • Research Site

    Muang, 50200

    Recruiting

  • Research Site

    Nonthaburi, 11000

    Recruiting

  • Research Site

    Pathum Thani, 12120

    Recruiting

Other trials in Thailand

Argentina4 sites, 4 recruiting

  • Research Site

    Ciudad de Buenos Aires, C1180AAX

    Recruiting

  • Research Site

    Florida, B1602DQD

    Recruiting

  • Research Site

    Rosario, 2000

    Recruiting

  • Research Site

    San Miguel de Tucumán, 4000

    Recruiting

Other trials in Argentina

Belgium4 sites, 4 recruiting

  • Research Site

    Ghent, 9000

    Recruiting

  • Research Site

    Leuven, 3000

    Recruiting

  • Research Site

    Liège, 4000

    Recruiting

  • Research Site

    Sint-Niklaas, 9100

    Recruiting

Other trials in Belgium

Philippines4 sites, 4 recruiting

  • Research Site

    Iloilo City, 5000

    Recruiting

  • Research Site

    Manila, 1000

    Recruiting

  • Research Site

    Quezon City, 1100

    Recruiting

  • Research Site

    Tondo, 1012

    Recruiting

Other trials in Philippines

Australia3 sites, 3 recruiting

  • Research Site

    Birtinya, 4575

    Recruiting

  • Research Site

    Macquarie University, 2109

    Recruiting

  • Research Site

    South Brisbane, 4101

    Recruiting

Other trials in Australia

Malaysia3 sites, 3 recruiting

  • Research Site

    Bandar Puncak Alam, 42300

    Recruiting

  • Research Site

    Kuala Lumpur, 59100

    Recruiting

  • Research Site

    Sibu, 96000

    Recruiting

Other trials in Malaysia

Netherlands3 sites, 2 recruiting

  • Research Site

    Amsterdam, 1081 HV

    Recruiting

  • Research Site

    Rotterdam, 3015 GD

    Recruiting

  • Research Site

    Zutphens, 7207 AE

    Withdrawn

Other trials in Netherlands

About this study

Official title: A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Read the detailed description

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

This Phase IIb study aims to assess the efficacy, safety, and PK of 2 dosage regimens of AZD0292 administered IV, as compared to placebo in participants 12 years of age and older.

The primary population of this study will be PsA-colonized NCFBE patients, a bronchiectasis group with frequent pulmonary exacerbations due to chronic PsA airway colonization. These PsA associated pulmonary exacerbations contribute to a decline in lung function, impair quality of life and increase mortality, highlighting the urgent need for effective therapeutic options. To investigate the broader applicability of AZD0292, bronchiectasis patients with CF who are colonized with PsA will be also included as a non-powered exploratory group in this Phase IIb study.

Being tested
AZD0292, Placebo
Keywords
Bronchiectasis Chronic Pseudomonas Aeruginosa Colonization

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AZD0292Biological

    AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

  • PlaceboOther

    Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

Study groups in NCT07088926
Study groupRoleWhat they receive
High-doseExperimentalHigh-Dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.
Receives: Biological: AZD0292
Low-doseExperimentalLow-dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.
Receives: Biological: AZD0292
PlaceboPlacebo comparatorPlacebo administered starting on Day 1, subsequent administrations per schedule of assessments.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Annualized rate of exacerbations over a variable follow-up time

    To evaluate the effect of AZD0292 compared to placebo on the rate of moderate or severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA.

    Measured: Min 28 weeks, max 52 weeks

Secondary outcomes (7)

  1. Annualized rate of severe exacerbations over a variable follow-up time

    To evaluate the effect of AZD0292 compared to placebo on severe exacerbations in participants with NCFBE and chronic colonization with PsA

    Measured: Min 28 weeks, max 52 weeks

  2. Change from baseline in QOL-B-RSS

    To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by QoL-B-RSS over the observation period

    Measured: Over the observation period (Week 0 to Final Dose+4 weeks)

  3. Change from baseline in SGRQ score

    To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by SGRQ over the observation period.

    Measured: Over the observation period (Week 0 to Final Dose +4 weeks)

  4. Time to first moderate or severe exacerbation

    To evaluate the effect of AZD0292 compared to placebo on time to first pulmonary exacerbation in participants with NCFBE and chronic colonization with PsA.

    Measured: Through study completion (Final Dose +24 weeks)

  5. Serum PK Concentrations

    To evaluate the PK of IV doses of AZD0292 in participants with bronchiectasis and chronic colonization with PsA

    Measured: At specified timepoints between Week 0 and Final Dose+12 weeks

  6. Incidence of ADA and ADA titers to AZD0292

    To evaluate the immunogenicity of IV doses of AZD0292 in participants with bronchiectasis and chronic colonization with PsA

    Measured: At specified timepoints between Week 0 and Final Dose +12 weeks

  7. Incidence of AEs, SAEs, AESIs and MAAEs

    To assess the safety of AZD0292 compared with placebo in participants with bronchiectasis and chronic colonization with PsA

    Measured: Occurrence of AEs; first dose through 12 weeks after last study intervention administration. Occurrence of SAEs, AESIs, and MAAEs; through study completion (Final Dose+24 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jul 2025
  2. Study start6 Nov 2025
  3. Primary completion9 Dec 2027 (estimated)
  4. Study completion14 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
D7700C00003 is a multicenter, randomized, Phase IIb, double-blind, placebo-controlled, parallel, multidose study to evaluate the efficacy, safety, and PK of AZD0292 compared with placebo in participants with bronchiectasis and chronic PsA colonization. The study will enroll up to 435 bronchiectasis participants.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
435 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07088926
Sponsor's protocol ID
D7700C00003
Acronym
CLEAR
Status last verified
Sep 2026
First submitted
17 Jul 2025
Last updated
2 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Publications

  • Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018 Jan 31;51(2):1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb.

    PubMed 29386336

  • Artaraz A, Crichton ML, Finch S, Abo-Leyah H, Goeminne P, Aliberti S, Fardon T, Chalmers JD. Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST). Respir Res. 2020 Jan 13;21(1):18. doi: 10.1186/s12931-019-1272-y.

    PubMed 31931782

  • Bellelli G, Chalmers JD, Sotgiu G, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Skrbic D, Lombi A, Pane F, Obradovic D, Fardon TC, Rutherford RM, Pesci A, Aliberti S. Characterization of bronchiectasis in the elderly. Respir Med. 2016 Oct;119:13-19. doi: 10.1016/j.rmed.2016.08.008. Epub 2016 Aug 17.

    PubMed 27692133

  • CFFPR 2023 Cystic Fibrosis Foundation Patient Registry. Bethesda, MD. 2023 Annual Data Report. Available at https://www.cff.org/media/34491/download.

  • Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85. doi: 10.1164/rccm.201309-1575OC.

    PubMed 24328736

  • Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015 May;45(5):1446-62. doi: 10.1183/09031936.00119114. Epub 2015 Mar 18.

    PubMed 25792635

  • Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ. Bronchiectasis. Nat Rev Dis Primers. 2018 Nov 15;4(1):45. doi: 10.1038/s41572-018-0042-3.

    PubMed 30442957

  • Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ. Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC.

    PubMed 29357265

  • Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018 Sep;6(9):715-726. doi: 10.1016/S2213-2600(18)30053-5. Epub 2018 Feb 23.

    PubMed 29478908

  • Chawla K, Vishwanath S, Manu MK, Lazer B. Influence of pseudomonas aeruginosa on exacerbation in patients with bronchiectasis. J Glob Infect Dis. 2015 Jan-Mar;7(1):18-22. doi: 10.4103/0974-777X.150885.

    PubMed 25722615

  • Choate R, Aksamit TR, Mannino D, Addrizzo-Harris D, Barker A, Basavaraj A, Daley CL, Daniels MLA, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, McShane PJ, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Stone G. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. Respir Med. 2021 Feb;177:106285. doi: 10.1016/j.rmed.2020.106285. Epub 2020 Dec 24.

    PubMed 33401148

  • Choi H, Xu JF, Chotirmall SH, Chalmers JD, Morgan LC, Dhar R. Bronchiectasis in Asia: a review of current status and challenges. Eur Respir Rev. 2024 Sep 25;33(173):240096. doi: 10.1183/16000617.0096-2024. Print 2024 Jul.

    PubMed 39322263

  • Ciofu O, Tolker-Nielsen T. Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics. Front Microbiol. 2019 May 3;10:913. doi: 10.3389/fmicb.2019.00913. eCollection 2019.

    PubMed 31130925

  • DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25.

    PubMed 22734046

  • Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002 Aug;34(2):91-100. doi: 10.1002/ppul.10127.

    PubMed 12112774

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AZD0292 in people with Bronchiectasis With Pseudomonas Aeruginosa Colonization, run by AstraZeneca at 186 sites in 25 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 186 sites in United States, Japan, Brazil, Germany, Peru and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Annualized rate of exacerbations over a variable follow-up time (time frame: Min 28 weeks, max 52 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07088926, which also lists 40 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in